constrained
Standard VC-backed-private-company constraint (investor-controlled cap table across three funding tranches, board oversight implied, runway-dependent -- no revenue disclosed to self-fund). Reinforced by a second, non-financial constraint specific to this actor: real regulatory exposure -- Ash was pulled from the UK market in Jan-2026 over regulatory concerns, and the FDA was separately reviewing a therapy-chatbot risk framework in Nov-2025 that could constrain the US market too. No evidence of founder-controlled or free-optionality structure found.
Sourced figures 3
- a16z.com + Slingshot AI Press page (cross-checked) three VC funding tranches (a16z-led x2, then Radical Ventures + Forerunner Ventures-led), no revenue disclosed
- STAT News via Google News RSS Slingshot pulls therapy chatbot Ash out of the U.K. over regulatory concerns
- coverage via Google News RSS FDA advisers examined risks associated with therapy chatbots, considering a regulatory framework
the working
Basis
Standard VC-backed-private-company constraint (investor-controlled cap table across three funding tranches, board oversight implied, runway-dependent -- no revenue disclosed to self-fund). Reinforced by a second, non-financial constraint specific to this actor: real regulatory exposure -- Ash was pulled from the UK market in Jan-2026 over regulatory concerns, and the FDA was separately reviewing a therapy-chatbot risk framework in Nov-2025 that could constrain the US market too. No evidence of founder-controlled or free-optionality structure found.
Threads 1
A claim is one metric we assert about a node — the value is the summary, this page is the receipt. Sourced from kestrel; supersedes-history not yet shown. Back to Slingshot AI.